2017 ESMO Congress

bladder cancer

ESMO 2017: KEYNOTE-045: Updated Results Support Pembrolizumab as Second-Line Treatment in Advanced Urothelial Cancer

Mature results from the KEYNOTE-045 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract LBA37_PR) confirmed significantly longer survival in patients ...

palliative care
lung cancer

ESMO 2017: 'Triggers': A New Tool to Assess Patients’ Palliative Needs

A new tool to identify patients who would benefit from early palliative care was presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract LBA54_PR). The so-call...

issues in oncology

ESMO 2017: Patients Struggle With Key Aspects of Clinical Trial Methodology

Clinical trials are fundamental to the development of new treatments for cancer, yet the annual accrual to cancer clinical trials worldwide is low, estimated at 3%–5%. A nationwide study in Irel...

head and neck cancer

ESMO 2017: KEYNOTE-040 Evaluates Pembrolizumab in Head and Neck Cancer

Immunotherapy with the checkpoint inhibitor pembrolizumab (Keytruda) may be a better option than standard treatments for patients whose head and neck cancer has spread or recurred after an initial rou...

issues in oncology

ESMO 2017: Abdominal to Peripheral Fat Ratio May Predict Risk of Cancer Diagnosis in Postmenopausal Women

Body fat distribution in the trunk is more influential than body weight when it comes to cancer risk in postmenopausal women, according to a study presented at the European Society for Medical Oncolog...

breast cancer

ESMO 2017: MONARCH 3: Abemaciclib as Initial Therapy Improves Outcome in Endocrine-Sensitive Advanced Breast Cancer

The results of the MONARCH 3 trial, presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract 236O_PR), showed that adding the cyclin-dependent kinase (CDK) 4/6 i...

issues in oncology
survivorship

ESMO 2017: NOR-CAYACS Trial: Factors That May Limit Work Ability of Young Adult Cancer Survivors

Factors that may limit the ability of young adult cancer survivors to work were reported at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract 1110PD_PR). Late side ef...

gynecologic cancer

ESMO 2017: Study Confirms Chemoradiation Is Best Treatment for Locally Advanced Cervical Cancer

A 14-year randomized trial in more than 600 patients has concluded that chemoradiation should remain the standard treatment for patients with locally advanced cervical cancer. The findings were report...

issues in oncology
supportive care

ESMO 2017: Patients May Feel Psychosocial Impact of Chemotherapy More Acutely Than Physical Side Effects

The preliminary results of a study presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid show that sociopsychological factors have become more significant for patients ...

gastrointestinal cancer

ESMO 2017: Pembrolizumab Shows Promising Response Rate in Pretreated Metastatic Gastric Cancer

Pembrolizumab (Keytruda) has shown a promising response rate in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented at the 2017 ...

breast cancer

ESMO 2017: Adding Taselisib to Neoadjuvant Letrozole Improves Outcomes in Early Breast Cancer

Adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both estrogen receptor–positive and HER2-negative, according to result...

prostate cancer

ESMO 2017: Patients With High-Risk Prostate Cancer May Benefit From Addition of Docetaxel or Abiraterone/Prednisolone to Long-Term Hormone Therapy

Patients with high-risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the European Soc...

issues in oncology

ESMO 2017: DNA Sequencing Could Open Up New Drug Indications for Patients With Rare Cancers

Due to DNA sequencing, patients with rare cancers for which no standard treatment is available could receive existing therapies that work in patients treated for different cancers but who carry the sa...

issues in oncology

Bonnie S. Glisson, MD, on HPV-16+ Cancer: Study Results

Bonnie S. Glisson, MD, of The University of Texas MD Anderson Cancer Center, discusses a clinical trial on the combination of ISA101, an HPV-16 vaccine, and nivolumab for patients with incurable HPV-1...

breast cancer

Judy E. Garber, MD, MPH, on Triple-Negative Breast Cancer: An Update

Judy E. Garber, MD, MPH, of Dana-Farber Cancer Institute, offers expert perspectives on the role of PARP inhibitors in treating triple-negative breast cancer.

kidney cancer

Toni K. Choueiri, MD, on RCC: Results From the CABOSUN Trial

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses updated overall survival results on cabozantinib vs sunitinib as initial targeted treatment for patients with metastatic renal cell car...

lung cancer

Luis G. Paz-Ares, MD, PhD, on NSCLC: Results of the PACIFIC Trial

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 De Octubre, discusses phase III study findings on durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresect...

gynecologic cancers

Eric Pujade-Lauraine, MD, PhD, on Ovarian Cancer: Results From the SOLO2 Trial

Eric Pujade-Lauraine, MD, PhD, of the Université Paris Descartes, discusses phase III study findings on the efficacy of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovaria...

lung cancer

Michèle Beau-Faller, MD, PhD, on NSCLC: Biomarker Findings From the French Cooperative Thoracic Intergroup

Michèle Beau-Faller, MD, PhD, of the Hôpital de Hautepierre & Institut Régional du Cancer, discusses study results on ultrasensitive detection of EGFR T790M mutation by droplet digital PCR in TKI ...

skin cancer

ESMO 2017: Combination Targeted Adjuvant Therapy Doubles Relapse-Free Survival in Stage III Melanoma

Combination targeted adjuvant therapy with dabrafenib (Tafinlar) and trametinib (Mekinist) doubles relapse-free survival in patients with stage III BRAF-mutant melanoma, according to late-breaking res...

skin cancer

ESMO 2017: Adjuvant Nivolumab Superior to Ipilimumab in Surgically Resected Stage III/IV Melanoma

Adjuvant nivolumab (Opdivo) is superior to standard-of-care ipilimumab (Yervoy) in patients with surgically resected stage III/IV melanoma who are at high risk of relapse, according to late-breaking r...

skin cancer

Jeffrey S. Weber, MD, PhD, on Melanoma: Results of the CheckMate 238 Trial

Jeffrey S. Weber, MD, PhD, of New York University’s Langone Medical Center, discusses study results on adjuvant therapy with nivolumab vs ipilimumab after complete resection of stage III/IV melanoma (...

issues in oncology

ESMO 2017: Some Stroke Survivors May Have Underlying Cancer

Some stroke survivors may have underlying cancer, according to an observational study presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract 1412P_PR). &ldquo...

gynecologic cancer

ESMO 2017: Rucaparib Boosts Progression-Free Survival in BRCA-Mutant Recurrent Ovarian Cancer

Rucaparib (Rubraca) maintenance therapy increases progression-free survival in BRCA-mutant recurrent ovarian cancer by 77%, according to late-breaking results from the ARIEL3 trial reported at the Eur...

gastroesophageal cancer

ESMO 2017: MIRO Trial: 3-Year Outcomes Favor Laparoscopic Surgery for Esophageal Cancer

Patients requiring surgery for esophageal cancer fare better after undergoing a hybrid minimally invasive esophagostomy compared to an open esophagostomy, according to long-term results of the MIRO tr...

gynecologic cancer

ESMO 2017: ICON8 Trial Reaffirms Standard Chemotherapy Dosing in Ovarian Cancer

Caucasian women with ovarian cancer can safely stick to the standard every-3-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the pha...

lung cancer

ESMO 2017: ALEX and ALUR Trials: Alectinib Shows CNS Benefit in ALK-Positive NSCLC

Data from two separate phase III studies presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid show the particular central nervous system (CNS) activity of alectinib (A...

kidney cancer

Bernard J. Escudier, MD, on RCC: Expert Perspective on Key Papers

Bernard J. Escudier, MD, of Gustave Roussy, offers a roundup of the important papers on renal cell cancer presented at this year's ESMO Congress.

prostate cancer

Cora N. Sternberg, MD, on Prostate Cancer Treatment Findings: Expert Perspective

Cora N. Sternberg, MD, of the San Camillo Forlanini Hospital, summarizes a session on the STAMPEDE and LATITUDE trials, as well as a third trial on docetaxel with androgen suppression for localized pr...

gynecologic cancers

Domenica Lorusso, MD, PhD, on Cervical Cancer: Results From a Trial on Treatment Regimens

Domenica Lorusso, MD, PhD, of the National Cancer Institute of Milan, discusses neoadjuvant chemotherapy followed by surgery vs concurrent cisplatin and radiation therapy in patients with stage IB2 to...

kidney cancer

Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial

Robert A. Figlin, MD, of Cedars-Sinai Medical Center, discusses an interim analysis of phase III findings on rocapuldencel-T, an individualized immunotherapy, for newly diagnosed patients with metasta...

kidney cancer

Bernard J. Escudier, MD, on RCC: Results From the CheckMate 214 Trial

Bernard J. Escudier, MD, of Gustave Roussy, discusses efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk...

skin cancer

Karl D. Lewis, MD, on Melanoma: Results From the BRIM8 Trial

Karl D. Lewis, MD, of the Anschutz Cancer Pavilion, discusses study findings on adjuvant vemurafenib in patients with completely resected BRAF V600–positive melanoma at high risk for recurrence (Abstr...

gynecologic cancers

Andrew R. Clamp, PhD, on Gynecologic Cancers: Results of the ICON8 Trial

Andrew R. Clamp, PhD, of The Christie NHS Foundation Trust, discusses his phase III study findings on dose-dense chemotherapy integration in first-line treatment of epithelial ovarian, fallopian tube,...

gynecologic cancers

Sandro Pignata, MD, PhD, on Ovarian and Related Gynecologic Cancers: Expert Perspective on Three Key Trials

Sandro Pignata, MD, PhD, of the Istituto Nazionale dei Tumori, summarizes findings from the ICON8 study on dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary p...

gynecologic cancers

Simone Koole, MD, on Ovarian Cancer: Results of the OVHIPEC Trial

Simone Koole, MD (and a PhD candidate), of the Netherlands Cancer Institute, discusses phase III findings on health-related quality of life after hyperthermic intraperitoneal chemotherapy for stage II...

skin cancer

Caroline Robert, MD, PhD, on Melanoma: Treatment With Nivolumab and Ipilimumab

Caroline Robert, MD, PhD, of Gustave Roussy, characterizes complete responses in patients with advanced melanoma who received the combination of nivolumab and ipilimumab, or nivolumab or ipilimumab al...

breast cancer

Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Results From the TONIC Trial

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negative breast cancer (Ab...

hepatobiliary cancer

Manuel Hidalgo, MD, PhD, on Biliary Tract Cancer: Results From the PRODIGY 12-ACCORD 18 Trial

Manuel Hidalgo, MD, PhD, of Harvard Medical School, discusses updated phase III findings on relapse-free survival and first overall survival results in adjuvant GEMOX (gemcitabine plus oxaliplatin) fo...

head and neck cancer

Robert I. Haddad, MD, on Head and Neck Cancer: Results of the CheckMate 141 Trial

Robert I. Haddad, MD, of Dana-Farber Cancer Institute, discusses phase III study results on treatment beyond disease progression with nivolumab in patients with recurrent or metastatic squamous cell c...

colorectal cancer

Jaafar Bennouna, MD, on Colorectal Cancer: Clinical Trial Findings on Targeted Treatments and Chemotherapy

Jaafar Bennouna, MD, of the University of Nantes, discusses findings from a phase II French study of bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in ...

pancreatic cancer

David A. Tuveson, MD, PhD, on Progress in Pancreatic Cancer: Expert Perspective

David A. Tuveson, MD, PhD, of Cold Spring Harbor Laboratory, discusses the most lethal of cancers. Although treatments are improving, the challenges are great, including early detection of this malign...

lung cancer

Luis G. Paz-Ares, MD, PhD, on NSCLC: Results of the PACIFIC Trial

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 De Octubre, discusses phase III study findings on durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresect...

breast cancer

Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Expert Perspective on CDK4 Inhibitors

Sibylle Loibl, MD, PhD, of the German Breast Group, summarizes a session she chaired in which the rationale to target CDK4, data on efficacy of the inhibitors, and triple combination therapy with PI3K...

gynecologic cancers

Mansoor Mirza, MD: Ovarian Cancer Treatment and Quality of Life

Mansoor Mirza, MD, of Copenhagen University Hospital, discusses quality of life in patients with recurrent ovarian cancer treated with niraparib (Abstract 930O).

lung cancer

ESMO 2017: Phase III IFCT-0302 Trial Assesses Minimal vs CT Scan–Based Follow-up for Completely Resected NSCLC

The optimal follow-up protocol for patients with completely resected non–small cell lung cancer (NSCLC) remains elusive after results of the IFCT-0302 trial, presented at the 2017 European Socie...

breast cancer

ESMO 2017: MINDACT Study in Early-Stage Breast Cancer Shows Even Small Tumors Can Be Aggressive

Even small tumors in the breast can be aggressive, according to a study in patients with early-stage breast cancer presented at the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid...

issues in oncology

ESMO 2017: Overuse of Tumor Marker Tests in Primary and Secondary Care

The vast majority of tumor marker tests in primary and secondary care are not necessary, according to a study presented at the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid (Abs...

Advertisement

Advertisement



Advertisement